Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line combination therapy study in advanced clear cell renal cell carcinoma
2022-502122-41-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 35
01
Overview
Phase 3, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing Pembrolizumab + belzutifan + lenvatinib, MK-1308A + lenvatinib and Pembrolizumab + lenvatinib (3 arms). Primary endpoints: Progression-Free Survival and Overall Survival. Planned start May 2021; status: authorised.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2022-502122-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502122-41-00.